ATTR-CM Archives - HealthQuill

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Bayer AG, a German multinational pharmaceutical and biotechnology company, has bought the marketing rights in Europe for a heart drug for $310 million to expand its cardiology portfolio.

Bayer acquires marketing rights for heart drug in Europe for $310 million

HQ Team March 4, 2024: Bayer AG, a German multinational pharmaceutical and biotechnology company, has bought the marketing rights in Europe for a.

by HealthQuill
March 4, 2024
0 Comments

Anglo-Swedish AstraZeneca Inc., and US-based Ionis Pharmaceuticals, announced the FDA has granted its nod for Wainua drug to treat nervous system impairment.

Drugs Health Pharma

USFDA clears AstraZeneca-Ionis’ drug for nervous system impairment

HQ Team December 22, 2023: Anglo-Swedish AstraZeneca Inc., and US-based Ionis Pharmaceuticals, announced the FDA has granted its nod for Wainua drug to.

by HealthQuill
December 22, 2023
0 Comments

About Us

Contact Info

Follow Us

Bayer acquires marketing rights for heart drug in Europe for $310 million

USFDA clears AstraZeneca-Ionis’ drug for nervous system impairment